

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/P7F08668082EN.html>

Date: May 2018

Pages: 79

Price: US\$ 2,000.00 (Single User License)

ID: P7F08668082EN

Abstracts

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline landscape.

Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4, 9 and 2 respectively.

Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Polyarticular Juvenile

Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development

Biocon Ltd

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Genor BioPharma Co Ltd

Livzon Pharmaceutical Group Inc

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Oncobiologics Inc

Oncodesign SA

Regeneron Pharmaceuticals Inc

Sandoz International GmbH

UCB SA

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drug Profiles

abatacept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sarilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RIP2 for Polyarthrititis, Gastrointestinal Disorders and

Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones

Featured News & Press Releases

Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd.1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Biocon Ltd, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences Inc, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Fresenius SE & Co KGaA, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Genor BioPharma Co Ltd, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Livzon Pharmaceutical Group Inc, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Momenta Pharmaceuticals Inc, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics Inc, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by UCB SA, H1 2018

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Biocon Ltd

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Genor BioPharma Co Ltd

Livzon Pharmaceutical Group Inc

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Oncobiologics Inc

Oncodesign SA

Regeneron Pharmaceuticals Inc

Sandoz International GmbH

UCB SA

I would like to order

Product name: Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/P7F08668082EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7F08668082EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970